A5070321144- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Sarcoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Immune cells in cancer
- PARP inhibition in cancer therapy
- Neuroendocrine Tumor Research Advances
- Angiogenesis and VEGF in Cancer
- Breast Cancer Treatment Studies
- Gut microbiota and health
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
Medical University of Graz
2016-2025
Graz University Hospital
2014-2022
PharmacoGenetics (China)
2014
Taipei Institute of Pathology
2014
University of Graz
2013
University of Southern California
2011
Inflammation has a critical role in the pathogenesis and progression of cancer. The lymphocyte to monocyte ratio (LMR) could be shown prognostic haematologic neoplasia. In this study, we analysed LMR with clinical outcome stage II III colon cancer patients. Three hundred seventy-two patients were included retrospective study. Kaplan–Meier curves multivariate Cox-regression analyses calculated for time recurrence (TTR) overall survival (OS). Including all patients, elevated preoperative was...
Inflammation has a critical role in the pathogenesis and progression of cancer. Recently, derived neutrophil to lymphocyte ratio (absolute count neutrophils divided by absolute white cell minus neutrophils; dNLR) been shown influence clinical outcome various cancer entities. In this study, we analysed dNLR with stage II III colon patients. Three-hundred seventy-two patients were included retrospective study. Kaplan–Meier curves multivariate Cox proportion analyses calculated for time...
Recent evidence indicates that the host inflammatory response has an important role in tumour progression. Elevated C-reactive protein (CRP) levels have been previously associated with poor prognosis several cancer types including small-scale studies pancreatic (PC) patients. The purpose of present study was to validate prognostic impact plasma CRP at date diagnosis on cancer-specific survival (CSS) a large cohort PC Data from 474 consecutive patients adenocarcinoma pancreas, treated between...
Increasing evidence indicates the involvement of inflammation and coagulation in cancer progression metastases. Inflammatory biomarkers hold great promise for improving predictive ability existing prognostic tools patients. In present study, we investigated several inflammatory indices with regard to their relevance predicting clinical outcome soft tissue sarcoma (STS) Three hundred forty STS patients were divided into a training set (n = 170) validation 170). Besides well-established...
Recent data indicate that tumour microenvironment, which is influenced by inflammatory cells, has a crucial role in cancer progression and clinical outcome of patients. In the present study, we investigated prognostic relevance preoperative neutrophil/lymphocyte (N/L) ratio on time to recurrence (TTR) overall survival (OS) soft-tissue sarcoma (STS) patients who underwent curative surgical resection.In all, 260 STS were included this retrospective study. Kaplan-Meier curves multivariate Cox...
Background: Biomarkers for predicting response to immune checkpoint inhibitors (ICI) are scarce and often lack external validation. This study provides a comprehensive investigation of pretreatment C-reactive protein (CRP) levels as well its longitudinal trajectories marker treatment disease outcome in patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy anti PD-1 or PD-L1 agents. Methods: We performed retrospective bi-center assess the association between...
There is substantial germline genetic variability within angiogenesis pathway genes, thereby causing interindividual differences in angiogenic capacity and resistance to antiangiogenesis therapy. We investigated polymorphisms genes involved VEGF-dependent -independent pathways predict clinical outcome tumor response metastatic colorectal cancer (mCRC) patients treated with bevacizumab oxaliplatin-based chemotherapy.A total of 132 first-line FOLFOX or XELOX were included this study. Genomic...
With growing evidence on the role of inflammation in cancer biology, presence a systemic inflammatory response has been postulated as having prognostic significance wide range types. The derived neutrophil to lymphocyte ratio (dNLR), which represents an easily determinable potential marker daily practise and clinical trials, never externally validated pancreatic (PC) patients.Data from 474 consecutive PC patients, treated between 2004 2012 at single centre, were evaluated retrospectively....
The concept of the involvement systemic inflammation in cancer progression and metastases has gained attraction within past decade. C-reactive protein (CRP), a non-specific blood-based marker inflammatory response, been associated with decreased survival several types. aim present study was to validate prognostic value pre-operative plasma CRP levels on clinical outcome large cohort soft-tissue sarcoma (STS) patients.Three hundred four STS patients, operated between 1998 2010, were...
Background The use and approval of immune checkpoint inhibitors for the treatment non-small cell lung cancer (NSCLC) depends on PD-L1 expression in tumor tissue. Nevertheless, often fails to predict response treatment. One possible explanation could be a change during course disease neglect reassessment. purpose this study was longitudinal analysis patients with relapsed NSCLC. Methods We retrospectively analyzed early-stage NSCLC subsequent relapse preoperative samples, matched surgical...
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity early clinical trials; however, their efficacy the real-world setting is unknown. Methods: A retrospective and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated a access program (named patient protocol) between August 2019 January 2021....
Improved efficacy has been shown for amivantamab and amivantamab-based combination therapies in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) compared to established treatment options clinical trials. However, a high risk of venous thromboembolism (VTE) was observed treated therapies, considerable differences VTE according the line systemic treatment, concomitant lazertinib, intravenous vs. subcutaneous administration. Based on early reports...
Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity B-lymphocytes is studied to a substantially lesser extent in respective setting. Thus, aim this study was evaluate peripheral blood B-cell subtypes as potential predictors ICI response.
Abstract Background The presence of autoantibodies in the serum cancer patients has been associated with immune‐checkpoint inhibitor (ICI) therapy response and immune‐related adverse events (irAEs). A prospective evaluation different entities is missing. Materials Methods In this cohort study, we included a pan‐cancer undergoing ICI treatment measured comprehensive panel at start time point first evaluation. induction (ANA, ENA, myositis, hepatopathy, rheumatoid arthritis) were assessed...
Squamous cell and adenocarcinomas of the lung develop different mechanisms during carcinogenesis to evade attacks immune system. Besides well-known check-point control programmed death 1 its ligand, many more mechanisms, acting either tumoricidal or in favor tumor progression, exist. Analysis profiles resected tissues bronchoalveolar lavage samples correlation between them with overall survival data was performed. In all this study, cells system expressed a tumor-cooperating phenotype. High...
In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment ALK tyrosine inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, use advanced ALK- or ROS1-positive cancer. Fifty-one...
Due to the success story of biomarker-driven targeted therapy, most NSCLC guidelines agree that molecular reflex testing should be performed in all cases with non-squamous cell carcinoma (non-SCC). In contrast, recommendations for squamous (SCC) vary considerably, specifically concerning exclusion patients certain age or smoking status from strategies. We a retrospective single-center study examining value an unselected cohort 316 consecutive lung SCC cases, tested by DNA- and RNA-based...
Accumulating evidence indicates an important pathophysiological role of fibrinogen on tumor cell progression and metastases in different types cancer. The aim the present study was to evaluate prognostic relevance pre-operative levels clinical outcome a large cohort STS patients.Two hundred ninety-four consecutive patients were retrospectively evaluated. Cancer-specific survival (CSS), disease-free (DFS), overall (OS) assessed using Kaplan-Meier curves Cox regression models. Finally, we...
Abstract Purpose: Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved colon carcinoma progression metastasis. We investigated polymorphisms a comprehensive panel of pathway genes to predict time recurrence (TTR) overall survival patients with stage II III carcinoma. Experimental Design: A total 742 consecutively collected were included this retrospective study. Genomic DNA was analyzed for 18 (SFRP, DKK 2 3, AXIN2, APC, MYC, TCF7L2,...